NASDAQ:PRTA - Prothena Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $28.29
  • Forecasted Upside: 26.73 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$22.32
▼ -0.28 (-1.24%)
1 month | 3 months | 12 months
Get New Prothena Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$28.29
▲ +26.73% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Prothena in the last 3 months. The average price target is $28.29, with a high forecast of $35.00 and a low forecast of $19.00. The average price target represents a 26.73% upside from the last price of $22.32.
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Prothena. This rating has held steady since December 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/28/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/26/2021Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$14.00 ➝ $28.00Medium
i
2/12/2021Jefferies Financial GroupUpgradeHold ➝ Buy$15.00 ➝ $30.00Low
i
2/4/2021HC WainwrightBoost Price TargetBuy$22.00 ➝ $33.00Low
i
Rating by A. Fein at HC Wainwright
2/2/2021OppenheimerBoost Price TargetOutperform$25.00 ➝ $35.00Low
i
2/2/2021BTIG ResearchUpgradeNeutral ➝ Buy$29.00Low
i
12/10/2020OppenheimerBoost Price Target$20.00 ➝ $25.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
12/7/2020HC WainwrightInitiated CoverageBuy$22.00Low
i
Rating by A. Fein at HC Wainwright
10/21/2020Cantor FitzgeraldBoost Price TargetPositive ➝ Overweight$20.00 ➝ $24.00High
i
9/13/2020OppenheimerReiterated RatingBuy$18.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/8/2020OppenheimerUpgradeMarket Perform ➝ Outperform$16.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/13/2020OppenheimerReiterated RatingHoldHigh
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/10/2020NomuraReiterated RatingBuy$19.00High
i
4/23/2020OppenheimerReiterated RatingHoldLow
i
1/1/2020Nomura SecuritiesReiterated RatingBuy$19.00Low
i
12/22/2019Evercore ISIReiterated RatingBuy$14.00High
i
11/27/2019Evercore ISIUpgradeIn-Line ➝ OutperformLow
i
11/19/2019Evercore ISIUpgradeIn-Line ➝ Outperform$14.00High
i
5/31/2019BarclaysReiterated RatingSell$9.00Low
i
5/16/2019Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by C. Duncan at Cantor Fitzgerald
3/4/2019Cantor FitzgeraldInitiated CoverageOverweight$13.77High
i
Rating by M. Lillis at Cantor Fitzgerald
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by M. Lillis at Cantor Fitzgerald
11/11/2018OppenheimerReiterated RatingHoldHigh
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/8/2018Cantor FitzgeraldReiterated RatingBuy$18.00Low
i
Rating by William Tanner at Cantor Fitzgerald
6/15/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Buy$14.00 ➝ $18.00High
i
5/25/2018OppenheimerReiterated RatingHoldLow
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/21/2018BarclaysDowngradeEqual Weight ➝ Underweight$12.00High
i
Rating by Geoff Meacham at Barclays PLC
5/9/2018OppenheimerReiterated RatingHoldHigh
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/24/2018Nomura SecuritiesLower Price TargetBuy ➝ Buy$87.00 ➝ $19.00High
i
4/24/2018WedbushLower Price TargetNeutral$46.00 ➝ $13.00High
i
Rating by D. Nierengarten at Wedbush
4/24/2018BTIG ResearchDowngradeBuy ➝ Neutral$77.00High
i
4/24/2018Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ Buy$78.00 ➝ $16.00High
i
Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
4/24/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$69.00 ➝ $14.00High
i
4/23/2018OppenheimerDowngradeOutperform ➝ HoldHigh
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/23/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$87.00High
i
4/23/2018BarclaysDowngradeOverweight ➝ Equal WeightHigh
i
4/23/2018Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
i
4/5/2018BarclaysLower Price TargetOverweight ➝ Overweight$70.00 ➝ $50.00Medium
i
3/21/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyHigh
i
Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
3/21/2018Cantor FitzgeraldReiterated RatingOverweight$69.00High
i
3/21/2018OppenheimerSet Price TargetBuy$70.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/15/2018OppenheimerSet Price TargetBuy$70.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/4/2018Cantor FitzgeraldReiterated RatingBuy$65.00High
i
12/20/2017Cantor FitzgeraldReiterated RatingBuy$65.00Medium
i
12/4/2017OppenheimerSet Price TargetBuy$70.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/20/2017WedbushDowngradeOutperform ➝ Neutral$75.00 ➝ $55.00N/A
i
Rating by D. Nierengarten at Wedbush
11/9/2017OppenheimerReiterated RatingBuy$70.00N/A
i
10/23/2017Deutsche Bank AktiengesellschaftSet Price TargetBuy$73.00N/A
i
Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
10/2/2017Jefferies Financial GroupReiterated RatingBuy$100.00Low
i
10/2/2017SunTrust BanksReiterated RatingBuy$75.00Low
i
10/1/2017Deutsche Bank AktiengesellschaftReiterated RatingBuyLow
i
Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
9/29/2017Royal Bank of CanadaReiterated RatingBuyHigh
i
9/29/2017BTIG ResearchLower Price TargetBuy ➝ Buy$80.00 ➝ $77.00High
i
Rating by Robert Hazlett at BTIG Research
9/28/2017Cantor FitzgeraldReiterated RatingBuy$79.00Medium
i
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$87.00High
i
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$83.00High
i
7/10/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$100.00Medium
i
7/6/2017OppenheimerReiterated RatingOutperform$70.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/19/2017BTIG ResearchInitiated CoverageBuy$80.00High
i
5/16/2017Piper Jaffray CompaniesReiterated RatingBuyMedium
i
Rating by Steven Breazzano at Piper Jaffray Companies
5/11/2017OppenheimerSet Price TargetBuy$70.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/12/2017Cantor FitzgeraldInitiated CoverageOverweight$86.00High
i
4/12/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$69.00Medium
i
4/6/2017OppenheimerSet Price TargetBuy$70.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/3/2017WedbushReiterated RatingOutperform$77.00High
i
Rating by D. Nierengarten at Wedbush
3/22/2017OppenheimerReiterated RatingBuyLow
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$87.00N/A
i
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
i
2/15/2017WedbushReiterated RatingOutperform$77.00N/A
i
Rating by D. Nierengarten at Wedbush
12/20/2016SunTrust BanksInitiated CoverageBuy$75.00N/A
i
12/6/2016WedbushReiterated RatingOutperform$77.00N/A
i
11/10/2016WedbushReiterated RatingOutperform$77.00N/A
i
11/3/2016Deutsche Bank AktiengesellschaftInitiated CoverageBuy$73.00N/A
i
10/31/2016WedbushReiterated RatingOutperform$77.00N/A
i
9/27/2016Credit Suisse GroupReiterated RatingBuy$65.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
9/26/2016WedbushReiterated RatingOutperform$77.00N/A
i
9/11/2016Credit Suisse GroupReiterated RatingBuy$65.00N/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
8/4/2016BarclaysBoost Price TargetOverweight$60.00 ➝ $70.00N/A
i
Rating by Geoff Meacham at Barclays PLC
8/4/2016UBS GroupReiterated RatingBuy$73.00N/A
i
Rating by Jeffrey Hung at UBS Group AG
8/3/2016WedbushReiterated RatingOutperform$77.00N/A
i
7/18/2016Royal Bank of CanadaReiterated RatingOutperform$95.00N/A
i
Rating by Michael Yee at Royal Bank of Canada
7/12/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
7/5/2016WedbushReiterated RatingOutperform$77.00N/A
i
6/22/2016Royal Bank of CanadaReiterated RatingBuyN/A
i
Rating by Michael Yee at Royal Bank of Canada
6/10/2016Royal Bank of CanadaReiterated RatingBuyN/A
i
Rating by Michael Yee at Royal Bank of Canada
6/10/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
6/10/2016UBS GroupReiterated RatingBuy$73.00N/A
i
5/13/2016BarclaysInitiated CoverageOverweight$60.00N/A
i
5/4/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Kennen MacKay at Credit Suisse Group AG
3/15/2016OppenheimerReiterated RatingOutperform$77.00N/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
(Data available from 2/27/2016 forward)
Prothena logo
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Read More

Today's Range

Now: $22.32
$22.26
$24.74

50 Day Range

MA: $16.15
$11.00
$24.00

52 Week Range

Now: $22.32
$7.10
$27.20

Volume

447,776 shs

Average Volume

468,350 shs

Market Capitalization

$891.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Prothena?

The following sell-side analysts have issued stock ratings on Prothena in the last twelve months: BTIG Research, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., Nomura, Oppenheimer Holdings Inc., Royal Bank of Canada, and Zacks Investment Research.
View the latest analyst ratings for PRTA.

What is the current price target for Prothena?

7 Wall Street analysts have set twelve-month price targets for Prothena in the last year. Their average twelve-month price target is $28.29, suggesting a possible upside of 26.7%. Oppenheimer Holdings Inc. has the highest price target set, predicting PRTA will reach $35.00 in the next twelve months. Nomura has the lowest price target set, forecasting a price of $19.00 for Prothena in the next year.
View the latest price targets for PRTA.

What is the current consensus analyst rating for Prothena?

Prothena currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRTA will outperform the market and that investors should add to their positions of Prothena.
View the latest ratings for PRTA.

What other companies compete with Prothena?

How do I contact Prothena's investor relations team?

Prothena's physical mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. The biotechnology company's listed phone number is 011-353-1236-2500 and its investor relations email address is [email protected] The official website for Prothena is www.prothena.com.